Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination
Karen Colwill, Yannick Galipeau, Matthew Stuible, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 3
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
Salma Sheikh‐Mohamed, Baweleta Isho, Gary Chao, et al.
Mucosal Immunology (2022) Vol. 15, Iss. 5, pp. 799-808
Open Access | Times Cited: 227
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
Roya Monica Dayam, Jaclyn C. Law, Rogier Goetgebuer, et al.
JCI Insight (2022) Vol. 7, Iss. 11
Open Access | Times Cited: 45
The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020–2023
Tanya Murphy, Hanna Swail, Jaspreet Jain, et al.
Canadian Medical Association Journal (2023) Vol. 195, Iss. 31, pp. E1030-E1037
Open Access | Times Cited: 35
A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens
Simon Joubert, Matthew Stuible, Simon Lord‐Dufour, et al.
Biotechnology and Bioengineering (2023) Vol. 120, Iss. 7, pp. 1746-1761
Open Access | Times Cited: 28
Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity
Sabryna Nantel, Salma Sheikh‐Mohamed, Gary Chao, et al.
Mucosal Immunology (2024) Vol. 17, Iss. 2, pp. 201-210
Open Access | Times Cited: 9
Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
Yannick Galipeau, Vinayakumar Siragam, Geneviève Laroche, et al.
EBioMedicine (2021) Vol. 74, pp. 103700-103700
Open Access | Times Cited: 50
Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
Kevin Yau, Christopher T. Chan, Kento T. Abe, et al.
Canadian Medical Association Journal (2022) Vol. 194, Iss. 8, pp. E297-E305
Open Access | Times Cited: 34
The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study
N. Almeida, Ian Schiller, Danbing Ke, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Outer membrane vesicles derived from Bordetella pertussis are potent adjuvant that drive Th1-biased response
Bernarda Pschunder, Lucia Locati, Oriana López, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults
Xuyang Tang, Abha Sharma, Maria Pasic, et al.
JAMA Network Open (2022) Vol. 5, Iss. 2, pp. e2146798-e2146798
Open Access | Times Cited: 28
COVID-19 vaccine immunogenicity in people with HIV
Cecilia T. Costiniuk, Joel Singer, Terry Lee, et al.
AIDS (2022) Vol. 37, Iss. 1, pp. F1-F10
Open Access | Times Cited: 28
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Martín A. Rossotti, Henk van Faassen, Anh Tran, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 27
Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults
Patrick Brown, Sze Hang Fu, Aiyush Bansal, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 24, pp. 2337-2339
Open Access | Times Cited: 26
Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies
Sun Jin Kim, Zhong Yao, Morgan Marsh, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
Vitaliy Matveev, Erik Z. Mihelic, Erika Benko, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107915-107915
Open Access | Times Cited: 16
Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada
Jessica A. Breznik, Ahmad Rahim, Tara Kajaks, et al.
Journal of the American Medical Directors Association (2023) Vol. 24, Iss. 5, pp. 753-758
Open Access | Times Cited: 11
Enhancing detection of SARS-CoV-2 re-infections using longitudinal sero-monitoring: demonstration of a methodology in a cohort of people experiencing homelessness in Toronto, Canada
Lucie Richard, Rosane Nisenbaum, Karen Colwill, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Role of N343 glycosylation on the SARS-CoV-2 S RBD structure and co-receptor binding across variants of concern
Callum M. Ives, Linh Nguyen, Carl A. Fogarty, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 4
When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study
Dawn M. E. Bowdish, Vinod Chandran, Carol Hitchon, et al.
The Journal of Rheumatology (2024) Vol. 51, Iss. 7, pp. 721-727
Open Access | Times Cited: 4
Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody
Traian Sulea, Jason Baardsnes, Matthew Stuible, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0266250-e0266250
Open Access | Times Cited: 19
COVID-19 Vaccine Coverage and Sociodemographic, Behavioural and Housing Factors Associated with Vaccination among People Experiencing Homelessness in Toronto, Canada: A Cross-Sectional Study
Lucie Richard, Michael Liu, Jesse Jenkinson, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1245-1245
Open Access | Times Cited: 17
Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern
Tyler M. Renner, Bassel Akache, Matthew Stuible, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study
Jeremiah Tan, Sasha Bernatsky, Jennifer L. Lee, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 104-104
Open Access
mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity
Philip Samaan, Chapin S. Korosec, Patrick Budylowski, et al.
Journal of Virology (2025)
Open Access
Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS‐CoV‐2 infection
Yannick Galipeau, Nicolas Castonguay, Pauline S. McCluskie, et al.
The FASEB Journal (2025) Vol. 39, Iss. 4
Open Access
Page 1 - Next Page

Scroll to top